Основные принципы терапии анкилозирующего спондилита (болезни Бехтерева)
暂无分享,去创建一个
[1] Sergey Solovyev,et al. ИЗУЧЕНИЕ РОЛИ ИММУНОГЕННОСТИ ИНФЛИКСИМАБА В ТЕРАПИИ АНКИЛОЗИРУЮЩЕГО СПОНДИЛИТА , 2016, RSP 2016.
[2] Н. В. Изможерова,et al. Сравнительная оценка влияния ряда препаратов с психотропным действием на центральную нервную систему экспериментальных животных, на фоне хронической алкогольной интоксикации в хронофармакологическом аспекте , 2016 .
[3] Елена Николаевна Александрова,et al. Эффективность адалимумаба при раннем ревматоидном артрите в зависимости от уровня препарата в сыворотке крови и наличия антилекарственных антител , 2014, RSP 2014.
[4] Junmin Chen,et al. Sulfasalazine for ankylosing spondylitis. , 2014, The Cochrane database of systematic reviews.
[5] W. Dhert,et al. Clinical outcome after traumatic spinal fractures in patients with ankylosing spinal disorders compared with control patients. , 2014, The spine journal : official journal of the North American Spine Society.
[6] M. Dougados,et al. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials , 2013, Annals of the rheumatic diseases.
[7] M. Dougados,et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force , 2013, Annals of the rheumatic diseases.
[8] V. Mazurov,et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1 , 2013, Annals of the rheumatic diseases.
[9] A. Deodhar,et al. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial , 2013, Annals of the rheumatic diseases.
[10] J. Braun,et al. Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial , 2013, Annals of the rheumatic diseases.
[11] D. Poddubnyy,et al. Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis – a five-year update , 2013, Expert opinion on biological therapy.
[12] J. Reveille,et al. The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. , 2013, Arthritis and rheumatism.
[13] J. Braun,et al. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in established disease. , 2013, Clinical and experimental rheumatology.
[14] J. Braun,et al. Remission and possible discontinuation of biological therapy in axial spondyloarthritis. , 2013, Clinical and experimental rheumatology.
[15] I. V. D. Horst-Bruinsma. Treatment of non-radiographic axial spondyloarthritis: it is only the beginning. , 2013 .
[16] I. E. van der Horst-Bruinsma. Treatment of non-radiographic axial spondyloarthritis: it is only the beginning , 2013, Annals of the rheumatic diseases.
[17] Jian Wang,et al. Management of hip involvement in ankylosing spondylitis , 2013, Clinical Rheumatology.
[18] Л. И. Мясоутова,et al. Опыт применения ритуксимаба у пациентов с анкилозирующим спондилитом , 2013 .
[19] J. Listing,et al. Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial , 2012, Annals of the rheumatic diseases.
[20] E. Pathan,et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis , 2012, Annals of the rheumatic diseases.
[21] A. Loft,et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry , 2012, Annals of the rheumatic diseases.
[22] Junmin Chen,et al. Methotrexate for ankylosing spondylitis. , 2013, The Cochrane database of systematic reviews.
[23] J. Braun,et al. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in early disease. , 2013, Clinical and experimental rheumatology.
[24] V. Bykerk,et al. Non-biologic disease-modifying antirheumatic drugs (DMARDs) improve pain in inflammatory arthritis (IA): a systematic literature review of randomized controlled trials , 2013, Rheumatology International.
[25] H. Direskeneli,et al. Conventional DMARD therapy (methotrexate‐sulphasalazine) may decrease the requirement of biologics in routine practice of ankylosing spondylitis patients: A real‐life experience , 2012, International journal of rheumatic diseases.
[26] A. Deodhar,et al. The “Knowns” and “Unknowns” of Biologic Therapy in Ankylosing Spondylitis , 2012, The American journal of the medical sciences.
[27] Шандор Федорович Эрдес. Эффективность адалимумаба при увеитах у больных анкилозирующим спондилитом , 2012 .
[28] G. Burmester,et al. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial , 2012, Annals of the rheumatic diseases.
[29] E. Märker-Hermann,et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort , 2012, Annals of the rheumatic diseases.
[30] F. Breedveld,et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011 , 2006, Annals of the rheumatic diseases.
[31] V. Preedy,et al. Nonsteroidal Anti-inflammatory Drugs , 2010 .
[32] M. Soubrier,et al. Mixed effect of tocilizumab in spondylarthritis. Comments about the article by Wendling et al. entitled "Short-term effect of IL-6 inhibition in spondylarthritis". Joint Bone Spine 2010;77:624-5. , 2012, Joint, bone, spine : revue du rhumatisme.
[33] P. Goupille,et al. Therapeutic Drug Monitoring of Infliximab in Spondyloarthritis: An Observational Open-Label Study , 2011, Therapeutic drug monitoring.
[34] Dongxue Wang,et al. Efficacy of etanercept in ankylosing spondylitis hip lesions. , 2011, Joint, bone, spine : revue du rhumatisme.
[35] M. Dougados,et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis , 2011, Annals of the rheumatic diseases.
[36] J. Braun,et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study , 2011, Annals of the rheumatic diseases.
[37] Анна Георгиевна Бочкова. Роль глюкокортикоидов в лечении спондилоартритов , 2011 .
[38] Piet Geusens,et al. Predicting the outcome of ankylosing spondylitis therapy , 2011, Annals of the rheumatic diseases.
[39] Andreas Krause,et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial , 2011, Annals of the rheumatic diseases.
[40] M. Weisman,et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010 , 2011, Annals of the rheumatic diseases.
[41] Array Ф. Эрдес,et al. Опыт длительной терапии инфликсимабом у больных анкилозирующим спондилитом , 2010, RSP 2010.
[42] M. Dougados,et al. Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis. , 2010, Rheumatology.
[43] W. Maksymowych,et al. A Double-blind, Placebo-controlled Trial of Low Dose Infliximab in Ankylosing Spondylitis , 2010, The Journal of Rheumatology.
[44] I. Olivieri,et al. Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study. , 2010, Rheumatology.
[45] Шандор Федорович Эрдес,et al. ПЕРВЫЙ ОПЫТ ПРИМЕНЕНИЯ АДАЛИМУМАБАУ БОЛЬНЫХ АНКИЛОЗИРУЮЩИМ СПОНДИЛИТОМ:КЛИНИЧЕСКОЕ И МРТ-СОПОСТАВЛЕНИЕ РЕЗУЛЬТАТОВ ТЕРАПИИ , 2010, RSP 2010.
[46] F. Erdes,et al. Ключевые слова: инфликсимаб, анкилозирующий спондилит, сакроилиит, энтезит, ремиссия EXPERIENCE WITH LONG-TERM INFLIXIMAB THERAPY IN PATIENTS WITH ANKYLOSING SPONDYLITIS , 2010 .
[47] A. Boonen,et al. Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery. , 2010, Rheumatology.
[48] D. Allan,et al. Concomitant cervical and thoracic spinal fractures in ankylosing spondylitis: A case report and review of literature , 2009 .
[49] G. Sapkas,et al. Surgical outcome after spinal fractures in patients with ankylosing spondylitis , 2009, BMC musculoskeletal disorders.
[50] T. Albert,et al. The Management of Spinal Injuries in Patients With Ankylosing Spondylitis or Diffuse Idiopathic Skeletal Hyperostosis: A Comparison of Treatment Methods and Clinical Outcomes , 2009, Journal of Spinal Disorders & Techniques.
[51] T. Kiaer,et al. Transpedicular closed wedge osteotomy in ankylosing spondylitis: results of surgical treatment and prospective outcome analysis , 2009, European Spine Journal.
[52] F. Oner,et al. Spinal fractures in patients with ankylosing spinal disorders: a systematic review of the literature on treatment, neurological status and complications , 2009, European Spine Journal.
[53] J. Sieper,et al. Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. , 2008, Arthritis and rheumatism.
[54] В. М. Дурлештер,et al. Первый опыт применения комбинированной хромоскопии у пациентов с гастроэзофагеальной рефлюксной болезнью , 2008 .
[55] K. Pavelka. [Early diagnosis of ankylosing spondylitis]. , 2006, Vnitrni lekarstvi.
[56] S. van der Linden,et al. Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy. , 2006, Best practice & research. Clinical rheumatology.
[57] M. Dougados,et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. , 2005, Arthritis and rheumatism.
[58] M. Dougados,et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis , 2003, Annals of the rheumatic diseases.
[59] M. Rudawaleit. [Early diagnosis of ankylosing spondylitis]. , 2003, Zeitschrift fur Rheumatologie.
[60] E. Veys,et al. Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: one year follow up , 2002, Annals of the rheumatic diseases.
[61] P. Emery,et al. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. , 2001, Arthritis and rheumatism.
[62] Яков Александрович Сигидин,et al. Контролируемая оценка эффективности сульфасалазина при анкилозирующем спондилоартрите , 2001 .
[63] H. Dagfinrud,et al. Physiotherapy interventions for ankylosing spondylitis. , 2001, The Cochrane database of systematic reviews.
[64] D. Baeten,et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study , 2000, Annals of the rheumatic diseases.
[65] D. Mosher,et al. Efficacy of sacroiliac corticosteroid injections in patients with inflammatory spondyloarthropathy: results of a 6 month controlled study. , 2000, The Journal of rheumatology.
[66] A. Sicard. [Spinal fractures]. , 1974, Journal de chirurgie.